CRDL

0.86262.28%
DG

David G. Elsley

President, CEO & Director

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of developing, financing, and managing all aspects of corporate development in biotechnology and high-growth organizations. Mr. Elsley founded Vasogen Inc. and served as its President from 1991 to March 7, 2007 and Chief Executive Officer from 1994 to March 7,2007. In 1990, Mr. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. Mr. Elsley assembled a team of management, directors, and scientific advisors comprising industry professionals and thought leaders from North America and Europe. Mr. Elsley was responsible for the scientific, clinical, and commercial development of Vasogen Inc. He was a Consultant. Mr. Elsley established the research and development infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies from concept to completion of international multi center pivotal phase III clinical trials involving 2,500 patients He served as a Director of Vasogen Inc. since January 1991. He holds a Master of Business Administration from the Richard Ivey School of Business, University of Western Ontario.

Positions